"The global non-alcoholic steatohepatitis (NASH) m
Post# of 148154
(Total Views: 602)
Posted On: 01/26/2021 10:51:22 PM
"The global non-alcoholic steatohepatitis (NASH) market generated $1,179 million in 2017, and is projected to reach $21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.
"At Present, there is no FDA-approved drug to treat NASH."
https://www.alliedmarketresearch.com/nonalcoh...%20alcohol.
"Another 20% to 30% of individuals progress to more advanced NASH fibrosis, and the final stage is NASH cirrhosis. It used to be thought that progression from early stage NAFLD to cirrhosis took decades, but recent studies have shown that some people progress rapidly within 2 years.Nov 1, 2019
"..commonly associated with risk factors like obesity, type 2 diabetes, hypertension, and hyperlipidemia. Some of the less known risk factors are obstructive sleep apnea, polycystic ovary syndrome, gout, and hypothyroidism, explained Syn.
"“The elephant in the room really is this condition,” Syn said. He added that the annual direct medical costs are estimated to be more than $100 billion."
"NASH has been staying under the radar since there is nothing approved yet to treat it, said Karen Watkins, PharmD, BCOP....
"..is not only a high prevalence of NASH, but it is also chronic in nature..NASH, she said, is not going away. This is not going to be a hot topic for just a few years. “It’s more likely to be the next diabetes.....patients with NASH..the majority of them are already obese..
https://www.ajmc.com/view/nash-has-gone-under...elists-say
"At Present, there is no FDA-approved drug to treat NASH."
https://www.alliedmarketresearch.com/nonalcoh...%20alcohol.
"Another 20% to 30% of individuals progress to more advanced NASH fibrosis, and the final stage is NASH cirrhosis. It used to be thought that progression from early stage NAFLD to cirrhosis took decades, but recent studies have shown that some people progress rapidly within 2 years.Nov 1, 2019
"..commonly associated with risk factors like obesity, type 2 diabetes, hypertension, and hyperlipidemia. Some of the less known risk factors are obstructive sleep apnea, polycystic ovary syndrome, gout, and hypothyroidism, explained Syn.
"“The elephant in the room really is this condition,” Syn said. He added that the annual direct medical costs are estimated to be more than $100 billion."
"NASH has been staying under the radar since there is nothing approved yet to treat it, said Karen Watkins, PharmD, BCOP....
"..is not only a high prevalence of NASH, but it is also chronic in nature..NASH, she said, is not going away. This is not going to be a hot topic for just a few years. “It’s more likely to be the next diabetes.....patients with NASH..the majority of them are already obese..
https://www.ajmc.com/view/nash-has-gone-under...elists-say
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼